| Elena Alekseevna Velazquez, CRNA | |
|
2615 Chester Ave, Bakersfield, CA 93301-2014 | |
| (661) 395-3000 | |
| Not Available |
| Full Name | Elena Alekseevna Velazquez |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 2615 Chester Ave, Bakersfield, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144596016 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | AP126358 (Texas) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP9241846 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital | Bakersfield, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Excelle Anesthesia Services Inc | 4688046774 | 25 |
| Comfort Anesthesia Associates Inc | 6002975489 | 64 |
News Archive
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'
› Verified 2 days ago
| Entity Name | Valley Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982617452 PECOS PAC ID: 8921184607 Enrollment ID: O20080320000291 |
News Archive
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'
› Verified 2 days ago
| Entity Name | Comfort Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043466550 PECOS PAC ID: 6002975489 Enrollment ID: O20081030000718 |
News Archive
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'
› Verified 2 days ago
| Entity Name | Excelle Anesthesia Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689317208 PECOS PAC ID: 4688046774 Enrollment ID: O20230220000629 |
News Archive
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elena Alekseevna Velazquez, CRNA 6412 Mount Bachelor Ln, Bakersfield, CA 93312-6183 Ph: () - | Elena Alekseevna Velazquez, CRNA 2615 Chester Ave, Bakersfield, CA 93301-2014 Ph: (661) 395-3000 |
News Archive
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.
After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'
› Verified 2 days ago
Mr. Bryan Elrod, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Alan Kim, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 11704 Nantwick Ct, Bakersfield, CA 93311 Phone: 714-269-0275 | |
Mr. Randy C. Willeby, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2128 Fax: 661-326-2129 | |
Lucille Petersen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Jane Fickes, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Sunita Bendale, MSN, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Muhammad Murtaza Rizvi, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 714-270-6337 |